More than half of people diagnosed with advanced melanoma now survive for at least 10 years when they receive a double hit of immunotherapy drugs, a trial has found.
The combined treatment has transformed survival rates for a form of skin cancer that once had a grim prognosis, with some patients now living long enough that they die from other causes.
